Dialogues

Aug 14, 2025, 03:06

How Pfizer’s BRAF-TOVI Breakthrough Is Revolutionizing MCC Treatment | Dr. Susan Zhang

In this insightful interview, Dr. Susan Zhang, Executive Medical Director at Pfizer, joins Emma Ter-Azaryan, YouTube Content Coordinator of OncoDaily, to discuss her groundbreaking work in oncology and the recent success of the BRAF-TOVI and MEKTOVI treatments for BRAF-mutant metastatic colorectal cancer.

Key Highlights:

Dr. Zhang’s inspiring transition from clinical medicine to drug development at Pfizer
The challenges faced in the Breakwater Study, from drug safety to enrolling patients with rare biomarkers
The future of colorectal cancer therapies at Pfizer, focusing on innovation in biomarker testing and personalized treatment options
The potential of liquid biopsy in advancing cancer diagnostics and treatment

biomarker testing BRAF-TOVI Breakwater Study cancer Cancer research cancer treatment clinical trials colorectal cancer Emma Ter-Azaryan Metastatic colorectal cancer OncoDaily Oncology pfizer Precision Medicine Susan Zhang

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2- Advanced Breast Cancer

Hubert Caron Retires from Roche-Genentech

Ramy Sedhom: Palliative Care Isn’t Just about When. It’s about Who, What, and How

Miriam Mutebi: One Small Grant, One Big Difference

Jasmine Kamboj: How We Bring Ourselves to the Table as Leaders